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Background. Self-expanding metal stents can alleviate malignant colonic obstruction in incurable patients and avoid palliative
stoma surgery. Objective. Evaluate stent eﬀectiveness and safety on palliation of patients with malignant colorectal strictures.
Design. Two prospective, one Spanish and one global, multicenter studies. Settings. 39 centers (22 academic, 17 community
hospitals)from13countries.Patients.Atotalof257patientswereenrolled,and255patientsweretreatedwithaWallFlexuncovered
enteral colonic stent. Follow-up was up to 12 months or until death or retreatment. Interventions(s). Self-expanding metal stent
placement. Main Outcome Measures. Procedural success, clinical success, and safety. Results. Procedural success was 98.4% (251).
Clinical success rates were 87.8% at 30 days, 89.7% at 3 months, 92.8% at 6 months, and 96% at 12 months. Overall perforation
ratewas5.1%.Overallmigrationratewas5.5%.Overalldeathrateduringfollow-upwas48.6%(124),with67.7%ofdeathsrelated
to the patient’s colorectal cancer, unrelated in 32.3%. Only 2 deaths were related to the stent or procedure. Limitations.N oc o n t r o l
group. Conclusions. The primary palliative option for patients with malignant colonic obstruction should be self-expanding metal
stent placement due to high rates of technical success and eﬃcacy in symptom palliation and few complications.
1.Introduction
Colorectal cancer is the second most prevalent cancer in the
world with incidence of 1 million new cases per year and
mortality of about 529,000 deaths [1].
Obstruction has been reported in 7–29% of patients with
colorectal cancer [2]. Patients with malignant large-bowel
obstruction tend to have advanced disease and be poor sur-
gical candidates.
Surgical colostomy is eﬀective, but mortality can be high.
In addition, a colostomy diminishes quality of life, and its
management poses diﬃculties for elderly and frail patients
[3, 4].
Thepatient presentseitherwithacute“total”obstruction
or subacute bowel obstruction. Severity of symptoms may
vary. Conventional therapies for relieving malignant col-
orectal obstruction include surgical resection (potentially
curative) or palliative colostomy. Resection is ideally carried
out as a single-stage procedure, with anastomosis to restore
bowel continuity, but multistage procedures may also be
undertaken, with resection and stoma formation in one2 Gastroenterology Research and Practice
procedure, followed by restoration of continuity in another
procedure. However, a signiﬁcant proportion of patients, up
to 50%, receiving a staged procedure never undergo reversal
of the colostomy [5]. In the emergency setting, surgery car-
ries a high-mortality (15–20%) and high-morbidity (45–
50%) risk with increased prevalence of intensive care stay,
infections, and complications related to stomas [4].
Endoscopic placement of SEMS to relieve colonic ob-
struction has been introduced more than 10 years ago [6].
Colonic SEMS may be used for palliation to eliminate the
need for stomas in incurable patients or to “bridge” patients
to elective single-stage surgery, most often without a stoma,
thereby signiﬁcantly reducing the mortality and morbidity
[7–9].
Although eﬀectiveness of the use of colonic SEMS in a
palliative or bridge to surgery indication is fairly broadly rec-
ognized, some have questioned the safety of colonic stenting,
particularly as it pertains to colonic perforation [10]. This
paper reports on the largest prospective series of treatment
with colonic SEMS per local standard of practice. The focus
of analysis is on broadness of applicability of the method and
patient safety.
2.MaterialsandMethods
2.1. Study Design. Two prospective, one Spanish and one
global, multi-center studies on the safety and eﬀectiveness of
theWallFlexEnteralColonicStent(BostonScientiﬁc,Natick,
MA, USA) were conducted using two identically structured
registries, the WallFlex-eR Colonic International Registry
and the WallFlex-eR Colonic Spanish Registry. Data was
collected over the course of 2 years and 9 months (interna-
tional registry) and 1 year and 11 months (Spanish registry).
Thirty-nine (39) centers (22 academic, 17 community hos-
pitals) from 13 countries enrolled patients with colorectal
strictures secondary to malignant disease who required stent
treatment either for a palliative (PAL) or bridge-to-surgery
(BTS) indication. Each patient was treated according to
the product directions for use by one of the 35 (89.7%)
gastroenterologists and 5 (12.8%) surgeons in the study.
This study was conducted as a registry where data was
collected for procedures performed per standard of practice.
Institutional review board (IRB) approval of the protocol
was obtained as required. Per guidance from their local IRB
departments, some centers did not require IRB approval
citing the registry nature of the studies, the use of a non-
investigational (approved) device, and treatment that is
standard of care for each patient included in the registries.
Documentation of patient consent to the procedure as well
as to the participation in the study or IRB waiver of the need
of such consenting to study participation was obtained.
Patient assessments were performed per each center’s
usual medical practices and according to the registry pro-
tocol. Data was collected at the time of stent placement
and included patient demographics, symptoms of colonic
obstruction,abilitytopassstool,treatmentspriortostenting,
tumorcharacteristicssuchasoriginandlocation,stentplace-
ment,andproceduredetails.Palliativepatientswerefollowed
for up to 12 months, namely at 30 days, 3 months, 6 months,
and 12 months, or until death or retreatment, whichever
occurred ﬁrst. Data collected during those visits included
symptoms of obstruction, stool passage, and retreatment
details. Complications and adverse events were collected and
documented for each patient as they occurred. Data was
prospectively added to the registries after each visit.
2.2.PatientPopulation. Patientswhomettheinclusioncrite-
ria of presenting with acute or symptomatic colonic obstruc-
tion secondary to malignant neoplasms and requiring either
palliative or bridge-to-surgery treatment with a stent were
enrolled.
Exclusion criteria consisted of the following: placement
of a previous colonic stent, enteral ischemia, suspected or
impending perforation, intra-abdominal abscess/perfora-
tion, contraindication to endoscopic treatment, and any use
of the stent other than those speciﬁcally outlined under
indications of use.
Atthetimeofenrollment,patientsweredeterminedtobe
either palliative (PAL) or bridge to surgery (BTS) based on
the malignant disease stage, age, surgical risk, and in some
cases due to patient’s choice. Data from the PAL cohort only
is presented in this paper.
2.3. Device and Stenting Procedure. SEMSs were placed by
the aid of ﬂuoroscopy and under direct visualization with
an endoscope. Conscious sedation was employed during the
majority of procedures in 80% (204) cases, and general
anesthesia was used on 12 patients. A 0.035-inch guidewire
was passed across the site of the stricture. The size of the
stricture was estimated, and the length and number of stents
needed to cross the stricture were determined. In a small
group of patients (9), the stricture was dilated prior to
stent placement using either a balloon or bougie dilator.
The WallFlex Enteral Colonic Stent delivery system was
then passed over the guidewire, through the endoscope
working channel and to the site of the stricture until the
postdeployment marker band was at the proximal end of the
stricture.Theexteriortubemarkerbandwasusedtoposition
the stent at the distal end of the stricture. The stent was then
deployed.
2.4. Outcomes Measures
2.4.1.ProceduralSuccess. Proceduralsuccesswasevaluatedas
a measure of successful endoscopic placement of the stent in
correct position.
2.4.2. Clinical Success. Eﬀectiveness of the stent was mea-
sured by its clinical success on the patient, deﬁned as pro-
viding adequate passage of stool (excellent, good, or fair)
from stent placement until death or 12 months without the
occurrenceofanydeviceorprocedure-relatedcomplications.
2.4.3. Safety Proﬁles. Major complications such as perfora-
tions and migrations were reported as they occurred and
were grouped in separate categories based on timing: up toGastroenterology Research and Practice 3
Table 1: Patient characteristics.
Measure Baseline 30-day follow-up 3-month follow-up 6-month follow-up 12-month follow-up
Symptoms of obstruction
Nausea 36.9% (93/252) 7.9% (15/191) 4.8% (6/125) 3.5% (3/85) 16.7% (6/36)
Vomiting 26.7% (67/251) 4.7% (9/192) 1.6% (2/125) 3.6% (3/84) 5.6% (2/36)
Constipation 77.1% (192/249) 17.2% (33/192) 13.6% (17/125) 20.0% (17/85) 28.6% (10/35)
Diarrhea 26.4% (66/250) 17.2% (33/192) 11.2% (14/125) 10.7% (9/84) 11.4% (4/35)
Abdominal pain/cramps 75.4% (190/252) 23.0% (44/191) 22.6% (28/124) 15.7% (13/83) 19.4% (7/36)
Bloating 57.1% (144/252) 12.6% (24/191) 4.8% (6/125) 7.1% (6/84) 11.4% (4/35)
Passage of stool
Good 5.1% (13/255) 77.7% (160/206) 84.1% (106/126) 83.7% (72/86) 75.0% (27/36)
Fair 9.4% (24/255) 11.2% (23/206) 11.1% (14/126) 11.6% (10/86) 19.4% (7/36)
Poor 83.9% (214/255) 7.8% (16/206) 3.2% (4/126) 1.2% (1/86) 2.8% (1/36)
Unknown 1.2% (3/255) 3.4% (7/206) 1.6% (2/126) 3.5% (3/86) 2.8% (1/36)
Missing 0.4% (1/255) 0.0% (0/255) 0.0% (0/255) 0.0% (0/255) 0.0% (0/255)
Lost to follow-up/death 0.0% (0/255) 19.2% (49/255) 50.6% (129/255) 66.3% (169/255) 85.9% (219/255)
6 hours after procedure and at each follow up point (30 days,
3 months, 6 months and 12 months).
2.5. Statistical Analyses. Summary statistics were computed
for either the enrolled population or the treated population,
depending on the measure being summarized. For cate-
gorical measures at each visit, summary statistics consist
of frequency and percent of responses in each category.
Unless otherwise noted, the denominator of a percentage is
the number of subjects with nonmissing values, based on
available follow-up data (evaluablepatients). For continuous
measures at each visit, summary statistics include sample
size, mean, median, standard deviation, minimum, and
maximum. The sample size is the number of nonmissing
values, based on evaluable patients, unless noted otherwise.
3. Results
Only results from the registries PAL cohort (255 patients
stented) are presented in this paper. Data from the registries
have been presented in two previous publications, one
presenting 30-day safety and eﬃcacy results including all
patients (447 patients) [11] and one presenting outcome
results of the BTS cohort (182 patients) [12].
3.1. Baseline Characteristics. In total, 257 patients, 141 from
theWallFlex-eRColonicInternationalRegistryand116from
the Spanish Registry, were enrolled with the intention of a
palliative treatment with a colonic stent. WallFlex colonic
stents were placed in 255 of the enrolled patients.
The cohort consisted of 155 (60.3%) male patients with
patient mean age of 73.5 ± 13.0a n da v e r a g eB M Io f2 5 .1 ±
4.2. Reported ASA scores were I in 17 (6.6%) cases, II in
99 (38.5%), III in 96 (37.4%), IV in 28 (10.9%) and V
in 1 (0.4%) cases. Symptoms of colonic obstruction were
presentedasfollows:nauseain93(36.9%)patients,vomiting
in 67 (26.7%), constipation in 192 (77.1%), diarrhea in
66 (26.4%), abdominal pain/cramps in 190 (75.4%), and
bloating in 144 (57.1%) patients. At baseline, previous treat-
ments for colo-rectal cancer were recorded in 38 (15%) of
patients, with the majority having undergone chemotherapy
(24), surgical resection (16), and/or radiation (3). Previous
lower abdominal and/or pelvic surgery was reported in 57
(22.4%) patients, and 27 (10.6%) patients had history of
chemotherapy and/or radiation for other malignant nonco-
lorectal disease.
Tumor etiology was described as intrinsic in 226 (89.3%)
and extrinsic in 27 (10.7%) of cases. The colo-rectal tumor
was mostly found in the left-sided colon (72.9%) which
included rectosigmoid junction, sigmoid colon, descending
colon, and splenic ﬂexure; rectal tumors were seen in 19.2%
of the cases and 10.2% in the proximal colon which included
transverse colon, hepatic ﬂexure, and ascending colon. The
most common dissemination of disease was reported as liver
metastasisin138(53.7%)patients,while97(37.7%)patients
had multiple metastases. Only 64 (24.9%) patients had local
colo-rectal cancer without proven metastasis, and decision
on palliative stent treatment was made in poor operative
candidates with severe comorbid medical illnesses.
3.2. Procedure Details. Twelve of the 255 treated patients
required two stents, and one patient received three stents.
The most commonly used stent size was of 9cm length and
25/30mm body/ﬂare diameter.
Prestent placement dilation was done in 9 (3.5%)
patients using either balloon or bougie. After stent deploy-
ment, the scope was passed through the stent in 43 (16.9%)
patients.
3.3. Follow-Up Visits. Of the 255 stented patients, 206 had
a 30-day follow-up visit, 126 were still being followed at 3
months, 86 at 6 months, and 36 patients reached the 12-
month follow-up point. Obstruction symptoms and passage
of stool of patients with evaluable data at each follow-up
interval are reported in Table 1.4 Gastroenterology Research and Practice
Table 2: Factors contributing to clinical failure.
Reason for Clinical Failure
Follow-up interval
30-day N = 24 3-month N = 12 6-month N = 5 12-month N = 1
Poor ability to pass stool 9 3 1 —
Complication/AE since stent placement 10 9 4 1
Poor stool and a complication/AE since
stent placement 5 ———
Table 3: Procedural and cumulative safety data.
Adverse event Procedure (n = 255) Cumulative (n = 94)
Perforation 1.2% (3/255) 13.8% (13/94)
Stent migration 0.4% (1/255) 12.8% (12/94)
Reobstruction due to
Ingrowth — 10.6% (10/94)
Overgrowth — 6.4% (6/94)
Faecal impaction — 8.5% (8/94)
Mucosal/bowel impaction into stent oral — 3.2% (3/94)
Mucosal/bowel impaction into stent anal — 1.1% (1/94)
Stent patent but second colonic obstruction — 2.1% (2/94)
Bleeding 0.4% (1/255) 4.3% (4/94)
Pain 1.2% (3/255) 4.3% (4/94)
Persistent obstruction 0.4% (1/255) 1.1% (1/94)
Other — 21.3% (20/94)
Total AEs 3.5% (9/255) 74.5% (70/94)
3.4. Procedural Success. Procedural success was achieved in
98.4% (251) of cases, of which 91.4% (233) were regarded as
having stents in optimal position.
3.5. Clinical Success. Clinical success, as a measure of
bowel function and lack of stent-related complications, was
assessed on 206, 126, 86, and 36 patients who had follow-
up visits at 30 days, 3 months, 6 months, and 12 months,
respectively. However, some of those patients were not
evaluable for clinical success due to either missing data on
bowel function or due to being lost to follow-up or death,
thus making the clinical success evaluable cohorts equal to
196 at 30 days, 116 at 3 months, 69 at 6 months, and 25 at 12
months.
The overall clinical success rate ranged from 87.8% to
96% depending on the follow-up period (87.8% at 30 days,
89.7% at 3 months, 92.8% at 6 months, and 96% at 12
months). Reasons for clinical failure are outlined in Table 2.
3.6. Safety. The overall perforation rate was 5.1% (13/255).
Table 3 lists the adverse events at each follow-up point.
Perforation rates were 1.2% at procedure, 3.3% at 30 days,
1.4% at 3 months, 0% at 6 months, and 2.5% at 12
months. There was 1 stent migration (0.4%) at the time of
procedure, 5 (2.3%) at 30 days, 4 (2.9%) at 3 months, 4
(4.0%) at 6 months, and no migrations at 12 months. The
overall migration rate was 5.5% (14/255). The main cause of
reobstruction was tumor in—or overgrowth (17%).
3.6.1. Mortality. One hundred and twenty-four (124) of
the 255 palliative patients died before the end of the 12-
month follow-up period. Reasons for death were attributed
to the patients’ colo-rectal cancer in 84 (67.7%) cases and
not related to colo-rectal cancer in 40 (32.4%) patients.
Only 2 deaths were related to the stent or procedure after a
perforation treated by surgery that occurred in one patient at
day 24 and in another patient at day 34 after stenting.
4. Discussion
SEMSs for palliation of malignant colo-rectal obstruction
are placed in patients with extensive metastatic disease and
in poor operative candidates with severe comorbid medical
illnesses.
Numerous series on the use of SEMSs have been
published, and many have been included in several reviews
[7–9]. Our results on the eﬀectiveness and eﬃcacy of the
WallFlex colonic stent are similar to previously reported
SEMS outcome results. Adverse events after stent placement
are common, from the serious perforation to minor clinical
problems with impaired bowel function. To illustrate the
beneﬁts of palliation with stents, we performed a Kaplan-
Meier analysis of time to clinical failure on treated patientsGastroenterology Research and Practice 5
0 7 14 30 60 90 120 150 180 270 365
Entered 196 196 194 185 171 138 118 90 82 70 41
Censored 0 2 6 7 19 16 21 7 11 25 23
At risk 196 195 191 181.5 161.5 130 107.5 86.5 76.5 57.5 29.5
Events 0 0 3 7 14 4 7 1 1 4 1
Events/month 0 0 12.9 13.1 14 4 7 1 1 1.3 0.3
Event-rate 0% 0% 1.6% 5.3% 13.4% 16.1% 21.3% 22.2% 23.3% 28.3% 31.7%
Event-free 100% 100% 98.4% 94.7% 86.6% 83.9% 78.7% 77.8% 76.7% 71.7% 68.3%
Std. error 0% 0% 0.9% 1.6% 2.5% 2.8% 3.3% 3.3% 3.5% 4% 5.1%
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Figure 1: The Kaplan-Meier analysis of time to clinical failure on treated patients.
shown in Figure 1. After 6 months more than 75% of treated
patients were event-free.
Regardless of the lack a of published large randomized
controlled trials on SEMSs, our data, together with previ-
ously reported data, suggests that SEMSs are the option of
choiceintheinitialmanagementofpatientswithobstructing
colon cancer and nonresectable metastases.
A recent publication from Nagula et al. [13] describes
a prospective observational cohort study of patients with
advanced malignancies undergoing either colon stent inser-
tion or surgical diversion for malignant large-bowel obstruc-
tion. The study was initially designed as a randomized trial
of colonic stent insertion and surgical palliation with an
observational arm for patients declining randomization.
Because of patient reluctance to being randomized and the
referring physician’s preference for either surgery or stent
placement, no patients were enrolled in the randomized
trial. The data was instead used to assess quality of life
(QoL) and longitudinal symptom control in patients after
colon stent placement or surgical diversion. The study
showed that neither stent placement nor surgery was associ-
ated with improvement in overall QoL, but stent placement
was associated with improved QoL related to gastrointestinal
function.
The decision for palliative care of patients with extensive
metastatic disease and those who are poor operative can-
didates should be individualized to each patient. The high
morbidity and mortality associated with emergency surgery
should be avoided. The patient’s present and future need for
chemotherapy also favors stent placement as it ensures that
immediate postprocedure chemotherapy will not be delayed
by a surgical procedure with the risk of even additional delay
due to complications.
Karoui et al. [14] analyzed the impact of stent placement
versus surgery with special reference to time to chemother-
apy administration. Patients who were treated with an SEMS
had shorter hospital stays than patients who had surgery
(median, 8.0 versus 13.5 days). In addition, the incidence of
stoma creation was lower compared to patients treated with
surgery(6% versus 37%). The median time to chemotherapy
administration was shorter after SEMS insertion than after
surgery (14.0 versus 28.5 days). There was no diﬀerence in
survival between the 2 groups. The authors reported a tumor
perforation requiring emergency surgery in two patients
(6%) treated with a SEMS and undergoing chemother-
apy and pointed out that the risk of tumor perforation
while receiving chemotherapy requires further attention.
Later publications also highlight this, especially if drugs
like Avastin (bevacizumab) where the antiangiogenic eﬀect
may weaken the bowel wall and predispose the bowel to
p e r f o r a t i o nb yS E M Sp r e s s u r e[ 15].
Faster and less complicated recovery after SEMS treat-
ment is also reported in a newly published paper by Ve-
mulapalli et al. [16]. The authors retrospectively reviewed
and compared data from patients with obstructing colon
cancer who either underwent insertion of a SEMS (n = 53)
or had surgery (n = 70) from 2002 to 2008. Patients in
the SEMS group had a signiﬁcantly shorter median hospital
stay (2 days) compared to the surgery group (8 days). In
addition; patients with SEMS had signiﬁcantly fewer acute
complications compared to the surgery group (8 versus
30%). Furthermore, the hospital mortality for the SEMS
group was 0% compared to 8.5% in patients who underwent
surgical decompression. There was no diﬀerence in survival
rates between the two groups.
5. Conclusions
Our data on eﬀectiveness and eﬃcacy on the use of self-
expanding metal stents for palliation of patients with malig-
nant colonic obstruction strongly support that stent place-
ment should be used as the primary palliative option, due
to the high technical success rate, low complication rate and
high eﬃcacy in symptom palliation.6 Gastroenterology Research and Practice
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